<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Gh Research Plc — News on 6ix</title>
    <link>https://6ix.com/company/gh-research-plc</link>
    <description>Latest news and press releases for Gh Research Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/gh-research-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835775d78dffbe2df0f79cb.webp</url>
      <title>Gh Research Plc</title>
      <link>https://6ix.com/company/gh-research-plc</link>
    </image>
    <item>
      <title>GH Research Announces Pricing of $117.5 Million Underwritten Offering</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announces-pricing-of-dollar1175-million-underwritten-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announces-pricing-of-dollar1175-million-underwritten-offering</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 GMT</pubDate>
      <description>DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United States of 6,527,779 of its ordinary shares at an offering price of $18.00 per share for total gross proceeds of approximately $117.5 million, before deducting underwriting discounts and commissions and off</description>
    </item>
    <item>
      <title>GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-welcomes-white-house-executive-order-to-accelerate-medical-treatments-for-serious-mental-illness</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-welcomes-white-house-executive-order-to-accelerate-medical-treatments-for-serious-mental-illness</guid>
      <pubDate>Mon, 20 Apr 2026 13:00:00 GMT</pubDate>
      <description>DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments (the Executive Order). The Executive Order directs coordinated feder</description>
    </item>
    <item>
      <title>GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announces-publication-of-phase-2b-results-for-mebufotenin-gh001-in-jama-psychiatry-and-reports-new-finding-of-severity-independent-efficacy-in-trd</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announces-publication-of-phase-2b-results-for-mebufotenin-gh001-in-jama-psychiatry-and-reports-new-finding-of-severity-independent-efficacy-in-trd</guid>
      <pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
      <description>Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology</description>
    </item>
    <item>
      <title>GH Research Reports Full Year 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-reports-full-year-2025-financial-results-and-provides-business-update-8</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-reports-full-year-2025-financial-results-and-provides-business-update-8</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congressesGH001 cleared by FDA for U.S. clinical</description>
    </item>
    <item>
      <title>GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announces-fda-lifts-clinical-hold-gh001-clearing-path-global-phase-3</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announces-fda-lifts-clinical-hold-gh001-clearing-path-global-phase-3</guid>
      <pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
      <description>GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating</description>
    </item>
    <item>
      <title>GH Research to Announce IND Status for GH001</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announce-ind-status-gh001-2026-01-02</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announce-ind-status-gh001-2026-01-02</guid>
      <pubDate>Fri, 02 Jan 2026 05:00:00 GMT</pubDate>
      <description>DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of</description>
    </item>
    <item>
      <title>GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-reports-third-quarter-2025-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-reports-third-quarter-2025-financial-results-and-provides-business</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>Engagement with FDA on GH001 IND complete response ongoingFull dataset from the Phase 2b clinical trial of GH001 in TRD reported in July 2025Long-term</description>
    </item>
    <item>
      <title>GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announces-novel-therapies-symposium-presentation-and-posters-2025-ecnp</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announces-novel-therapies-symposium-presentation-and-posters-2025-ecnp</guid>
      <pubDate>Thu, 09 Oct 2025 04:00:00 GMT</pubDate>
      <description>DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of</description>
    </item>
    <item>
      <title>GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-reports-second-quarter-2025-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-reports-second-quarter-2025-financial-results-and-provides-business</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>Global pivotal program initiation on track for 2026Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis</description>
    </item>
    <item>
      <title>GH Research Announces Global Pivotal Program Plans and Further Development Updates</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announces-global-pivotal-program-plans-and-further-development-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announces-global-pivotal-program-plans-and-further-development-updates</guid>
      <pubDate>Wed, 23 Jul 2025 04:00:00 GMT</pubDate>
      <description>Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with</description>
    </item>
    <item>
      <title>GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-submits-complete-ind-hold-response-fda-ahead-schedule-2025-06-20</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-submits-complete-ind-hold-response-fda-ahead-schedule-2025-06-20</guid>
      <pubDate>Fri, 20 Jun 2025 04:00:00 GMT</pubDate>
      <description>DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of</description>
    </item>
    <item>
      <title>GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announces-acceptance-pharmaceutical-pipeline-presentation-and-late</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announces-acceptance-pharmaceutical-pipeline-presentation-and-late</guid>
      <pubDate>Thu, 15 May 2025 04:00:00 GMT</pubDate>
      <description>DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of</description>
    </item>
    <item>
      <title>GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-reports-first-quarter-2025-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-reports-first-quarter-2025-financial-results-and-provides-business</guid>
      <pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
      <description>Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for</description>
    </item>
    <item>
      <title>GH Research Reports Full Year 2024 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-reports-full-year-2024-financial-results-and-provides-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-reports-full-year-2024-financial-results-and-provides-business-updates</guid>
      <pubDate>Thu, 27 Feb 2025 05:00:00 GMT</pubDate>
      <description>Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in</description>
    </item>
    <item>
      <title>GH Research Announces Pricing of $150 Million Public Offering</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announces-pricing-150-million-public-offering-2025-02-04</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announces-pricing-150-million-public-offering-2025-02-04</guid>
      <pubDate>Tue, 04 Feb 2025 05:00:00 GMT</pubDate>
      <description>DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of</description>
    </item>
    <item>
      <title>GH Research Announces Proposed Public Offering</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announces-proposed-public-offering-2025-02-03</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announces-proposed-public-offering-2025-02-03</guid>
      <pubDate>Mon, 03 Feb 2025 05:00:00 GMT</pubDate>
      <description>DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of</description>
    </item>
    <item>
      <title>GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announces-primary-endpoint-met-phase-2b-trial-gh001-trd-demonstrating-155</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announces-primary-endpoint-met-phase-2b-trial-gh001-trd-demonstrating-155</guid>
      <pubDate>Mon, 03 Feb 2025 05:00:00 GMT</pubDate>
      <description>Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8</description>
    </item>
    <item>
      <title>GH Research to Provide Update on Phase 2b Trial with GH001 in TRD</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-provide-update-phase-2b-trial-gh001-trd-2025-01-31</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-provide-update-phase-2b-trial-gh001-trd-2025-01-31</guid>
      <pubDate>Fri, 31 Jan 2025 05:00:00 GMT</pubDate>
      <description>DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment</description>
    </item>
    <item>
      <title>GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-announces-primary-endpoint-met-two-phase-2a-poc-trials-gh001-and</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-announces-primary-endpoint-met-two-phase-2a-poc-trials-gh001-and</guid>
      <pubDate>Fri, 10 Jan 2025 05:00:00 GMT</pubDate>
      <description>Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points</description>
    </item>
    <item>
      <title>GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/gh-research-plc/news/gh-research-reports-third-quarter-2024-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/gh-research-plc/news/gh-research-reports-third-quarter-2024-financial-results-and-provides-business</guid>
      <pubDate>Thu, 14 Nov 2024 05:00:00 GMT</pubDate>
      <description>Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical</description>
    </item>
  </channel>
</rss>